NOLA.com1d
New prostate cancer drug can extend life expectancy by 8 months, Baton Rouge doctor says
"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...
InformNNY on MSN1d
CNY man is first patient in US to receive new prostate cancer treatment
On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate ...
Medscape4d
FDA Approves Pluvicto for Earlier Use in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...
MPR2d
FDA Expands Approval of Pluvicto in PSMA-Positive Metastatic CRPC
The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...
BioPharma Dive6d
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
Fierce Pharma7d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
Explore more
STAT4d
Emotional whiplash for PTC Therapeutics
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
Healio6d
FDA expands Pluvicto indication for earlier use in patients with prostate cancer
The FDA approved a radioligand therapy for earlier use prior to chemotherapy in patients with prostate-specific membrane ...
Florida Cancer Specialists & Research Institute Expands Availability Of Advanced Radiopharmaceutical Therapies
Florida Cancer Specialists & Research Institute, LLC (FCS) continues to expand the availability of life-changing and ...
ASP Isotopes Inc. Completes Commissioning of First Quantum Enrichment Laser System and Starts Production of Commercial Samples of Ytterbium-176
Ytterbium-176 is a critical material used in the production of radioisotopes for oncology treatments, including Novartis’ Pluvicto. - The ...
Cancer Therapy Advisor4d
FDA Expands Approval of Pluvicto in PSMA-Positive mCRPC
The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.